IMAGING AGENT APPROVALS SHOULD BE BASED ON STRENGTH OF DATA PROVIDED TO PRACTITIONER, CORAR TELLS FDA CMTE.; WORKABLE POINTS DUE BY MID-JANUARY
This article was originally published in The Gray Sheet
FDA should "recognize that the preapproval, development and review process" of medical imaging agents "should not be based on clinical utility or specific diseases, but on the performance of the procedure in providing information to the practitioner," according to a Council on Radionuclides and Radiopharmaceuticals statement prepared for an Oct. 26 meeting of the agency's Medical Imaging Drugs Advisory Committee in Silver Spring, Maryland.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.